REGN Latest Press Releases

-- December 7, 2025 --

Lynozyfic (linvoseltamab) Monotherapy in Newly Diagnosed Multiple Myeloma (NDMM) Shows Impressive Responses, Supporting Rationale as a Potential Foundation in Frontline Treatment Globe Newswire 4:30 PM

-- December 1, 2025 --

Regeneron and Tessera Therapeutics to Jointly Develop TSRA-196, an Investigational Gene Editing Therapy for Alpha-1 Antitrypsin Deficiency (AATD) Globe Newswire 7:00 AM

-- November 25, 2025 --

Press Release: Sanofi and Regeneron's Dupixent approved as the first targeted medicine in the EU in over a decade for chronic spontaneous urticaria Globe Newswire 1:00 AM

Dupixent (dupilumab) Approved as the First Targeted Medicine in the European Union (EU) in Over a Decade for Chronic Spontaneous Urticaria (CSU) Globe Newswire 1:00 AM

-- November 19, 2025 --

EYLEA HD (aflibercept) Injection 8 mg Approved by FDA for the Treatment of Macular Edema Following Retinal Vein Occlusion (RVO) and for Monthly Dosing Across Approved Indications Globe Newswire 4:10 PM

Libtayo (cemiplimab) Approved in the European Union as First and Only Immunotherapy for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma (CSCC) with High Risk of Recurrence after Surgery and Radiation Globe Newswire 7:00 AM

-- November 13, 2025 --

Regeneron Highlights Progress at American Society of Hematology (ASH), with Updated Data in Multiple Myeloma, Lymphoma and Paroxysmal Nocturnal Hemoglobinuria Programs Globe Newswire 7:00 AM

-- November 8, 2025 --

Phase 2 Trials Demonstrating Antithrombotic Effect of Two Novel Regeneron Factor XI Antibodies Presented at American Heart Association Scientific Sessions and Published in The Lancet Globe Newswire 10:46 AM

-- November 7, 2025 --

Press Release: ACAAI: Sanofi and Regeneron's Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review Globe Newswire 8:00 AM

Dupixent (dupilumab) Pivotal Trial Met All Primary and Secondary Endpoints, Reducing Signs and Symptoms of Allergic Fungal Rhinosinusitis (AFRS); sBLA Accepted for FDA Priority Review Globe Newswire 8:00 AM

-- November 3, 2025 --

Regeneron Announces Investor Conference Presentations Globe Newswire 4:05 PM

-- October 31, 2025 --

Dupixent (dupilumab) Wins Prestigious 2025 Prix Galien USA Best Biotechnology Product Award Globe Newswire 7:00 AM

-- October 29, 2025 --

OPKO Health's ModeX Therapeutics Enters into Research Collaboration with Regeneron to Develop Multispecific Antibodies for Select Therapeutic Indications Globe Newswire 8:00 AM

-- October 28, 2025 --

Regeneron Reports Third Quarter 2025 Financial and Operating Results Globe Newswire 6:30 AM

-- October 17, 2025 --

Libtayo (cemiplimab) Recommended for EU Approval by the CHMP for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma (CSCC) with a High Risk of Recurrence After Surgery and Radiation Globe Newswire 7:30 AM

-- October 15, 2025 --

Regeneron Showcases Advances Across Oncology Portfolio and Pipeline at ESMO, Highlighting Novel and Patient-Focused Approach for Difficult-to-Treat Cancers Globe Newswire 7:00 AM

-- October 12, 2025 --

DB-OTO Results in the New England Journal of Medicine Showcase Dramatic and Sustained Improvements in Hearing and Speech Perception in Children with Profound Genetic Hearing Loss Globe Newswire 10:18 AM

-- October 8, 2025 --

Libtayo (cemiplimab-rwlc) Approved in the U.S. as First and Only Immunotherapy for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma (CSCC) with a High Risk of Recurrence After Surgery and Radiation Globe Newswire 2:31 PM

-- September 30, 2025 --

Regeneron to Report Third Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on October 28, 2025 Globe Newswire 4:05 PM

-- September 26, 2025 --

Evkeeza (evinacumab-dgnb) ANGPTL3 Antibody Approved in the U.S. for Children as Young as 1 Year Old with Ultra-Rare Form of High Cholesterol Globe Newswire 7:00 AM

-- September 22, 2025 --

Press Release: Sanofi and Regeneron's Dupixent to treat chronic spontaneous urticaria advances in EU with positive CHMP opinion Globe Newswire 12:30 AM

Dupixent (dupilumab) to Treat Chronic Spontaneous Urticaria (CSU) Advances in EU with Positive CHMP Opinion Globe Newswire 12:29 AM

-- September 19, 2025 --

Regeneron Donates Ebola Treatment for Use in Countries Most at Risk of Outbreaks Globe Newswire 7:00 AM

-- September 17, 2025 --

Results from Phase 2 COURAGE Trial Demonstrating Potential to Improve Quality of GLP-1 receptor agonist-induced Weight Loss by Preserving Lean Mass, Presented at EASD Globe Newswire 9:30 AM

Regeneron Announces Positive Phase 3 Trial in Adults with Ultra-Rare Genetic Disorder Fibrodysplasia Ossificans Progressiva (FOP), Demonstrating that Garetosmab Prevents Greater than 99% of Abnormal Bone Formation Globe Newswire 7:00 AM

-- September 9, 2025 --

REGENERON ALERT: Bragar Eagel & Squire, P.C. is Investigating Regeneron Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm Globe Newswire 5:46 PM

Libtayo (cemiplimab) Plus Chemotherapy Results at Five Years Reinforce Significant and Durable Improvements in Survival Outcomes for Advanced Non-small Cell Lung Cancer Globe Newswire 7:00 AM

-- September 8, 2025 --

Regeneron Advances Allergy Pipeline with Two Positive Phase 3 Trials Evaluating First-in-Class Antibody-Blockers of Cat and Birch Allergies Globe Newswire 6:30 AM

-- September 4, 2025 --

Regeneron Announces Updated Presentation Time for Upcoming Investor Conference Globe Newswire 4:05 PM

-- August 26, 2025 --

Regeneron Announces Positive Results from Phase 3 Trial in Generalized Myasthenia Gravis Globe Newswire 7:00 AM

-- August 20, 2025 --

EYLEA HD (aflibercept) Injection 8 mg Applications for Expanded U.S. Label and Prefilled Syringe Receive FDA Review Period Extension Globe Newswire 11:19 AM

-- August 7, 2025 --

Regeneron Announces Investor Conference Presentations Globe Newswire 4:05 PM

-- August 1, 2025 --

Regeneron Reports Second Quarter 2025 Financial and Operating Results Globe Newswire 6:30 AM

-- July 24, 2025 --

Regeneron Announces the 2025 Winners of the Regeneron Prize for Creative Innovation Globe Newswire 7:30 AM

QQQ ETF News, 7/24/2025 TipRanks 6:58 AM